The use of tumor genome profiling to identify actionable or targetable mutations in women with breast cancer is not ready for routine use in clinical practice.
Breast Cancer Targets
As more treatment options become available for metastatic HER2-positive breast cancer, some questions regarding the optimal sequencing of therapies remain.
The addition of bevacizumab to endocrine therapy did not prolong survival in postmenopausal women with advanced HER2-negative, HR–positive breast cancer.
Many women with breast cancer do not understand the details of their tumor characteristics or how they relate to specific treatment options, according to a new study.
Two recently published studies suggest that PIK3CA mutations cannot be used as a predictive biomarker to guide therapy in HER2-positive breast cancer.
Tamoxifen given to women at high risk for breast cancer lowered the rate of estrogen receptor (ER)-positive breast cancer diagnosis in the IBIS-I trial.
Fulvestrant improved overall survival compared with anastrozole, among women with treatment-naive, advanced, hormone receptor-positive breast cancer.
A study of triple-negative breast cancer patients found that adding bevacizumab to chemo resulted in higher pCR rates in those with basal-like disease.
The PD-1 inhibitor pembrolizumab showed activity and had an acceptable safety profile in heavily pretreated metastatic triple-negative breast cancer patients.
Results of a phase II study of a PI3K inhibitor in ER-positive breast cancer showed a trend toward improved progression-free survival.